← Markets

Johnson & Johnson

JNJ · NYSE

Market closed$253.04$3.07 (+1.23%)After hours $253.48 · +0.17%

Key statistics

Previous close$249.97
Open$252.39
Day high$255.66
Day low$251.96
52-week high$269.43
52-week low$162.78
Market cap609.12B
Volume7.52M
Average volume8.24M
P/E ratio23.58
Forward P/E18.28
EPS10.73
Dividend yield+2.07%

Market context

Why it moved

Johnson & Johnson shares rebounded and moved higher as investors reassessed the company's strong Q2 earnings beat and raised 2026 guidance, with analyst price target upgrades helping offset earlier concerns about the MedTech segment's disappointing performance.

MarketbeatSimplywallCoincodexFacebookMoomoo

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Johnson & Johnson shares edged higher on Friday, recovering from post-earnings weakness earlier in the week, as investors reassessed the company's strong Q2 results and raised full-year guidance. J&J reported adjusted EPS of $2.90 on revenue of $25.31 billion — both beating estimates — driven by standout pharmaceutical growth in Darzalex, Tremfya, and Spravato, and lifted its FY2026 EPS guidance to $11.60–$11.75 with revenue expected to surpass $100 billion for the first time. The rebound came despite a risk-off market backdrop weighed down by AI concerns and U.S.-Iran tensions, with healthcare emerging as a relative safe haven; UBS upgraded the sector citing improving fundamentals, and analysts including Raymond James and Guggenheim reiterated bullish ratings with price targets of $265–$270.

1.2281

July 17, 2026Johnson & Johnson closed modestly higher, recovering from an initial post-earnings dip as investors reassessed a strong Q2 beat. The company reported adjusted EPS of $2.90 on revenue of $25.31 billion, both topping consensus, with ex-Stelara Innovative Medicine growth exceeding 14% year-on-year and Tremfya delivering its first $2 billion sales quarter. Management raised FY2026 guidance to $101.1 billion in revenue and EPS of $11.60–$11.75 — on track to surpass $100 billion in annual sales for the first time. Multiple analysts lifted price targets post-earnings, including Morgan Stanley (to $294, Overweight), Scotiabank (to $305), and RBC ($287, Outperform), citing building IM momentum into 2027. Lingering concerns around MedTech cardio softness and talc litigation kept the initial reaction muted, but the stock found support alongside a broader healthcare sector rally led by UnitedHealth's strong Q2.

1.1942

July 16, 2026Johnson & Johnson fell despite delivering a strong Q2 beat, a classic 'sell the news' reaction after a ~25% year-to-date run heading into earnings. The company posted adjusted EPS of $2.90 (vs. $2.85 estimate) on record quarterly sales of $25.31 billion (+6.6% YoY), and raised full-year guidance to ~$101.1B in sales and $11.68 adjusted EPS at the midpoint — marking what CEO Joaquin Duato called a historic milestone toward $100B in annual revenue. Key growth drivers included oncology standout Darzalex ($4.2B) and Tremfya, which surged 72.5% to $2B, while Stelara biosimilar headwinds remained a drag. Several analysts raised price targets ahead of the print, with Citigroup at $298 and RBC at $287, suggesting elevated expectations may have set a high bar for the stock despite the operational outperformance.

-2.6906

July 15, 2026Johnson & Johnson edged lower ahead of its highly anticipated Q2 2026 earnings report due before the market open on July 15, with analysts expecting EPS of $2.85 on revenue of $25.06 billion. The pullback came despite a wave of bullish analyst activity — TD Cowen raised its price target to $300, RBC lifted its target to $287, and Citigroup raised its target to $298 — as investors appeared to book profits near recent highs. Broader healthcare sector weakness added pressure, with peer Abbott Labs declining sharply on litigation concerns, while an affirmed $45 million talc-mesothelioma verdict against J&J and Kenvue renewed legal risk sentiment around the stock.

-1.5207

July 14, 2026Johnson & Johnson edged higher on Monday, outperforming a broader market weighed down by U.S.-Iran tensions and oil price surges, as investors look ahead to the company's pivotal Q2 earnings report due Wednesday. Analyst conviction has been building, with TD Cowen raising its price target to $300, RBC Capital lifting its target to $287 with an Outperform rating, and Morgan Stanley increasing its target to $284 with an Overweight — all ahead of results where consensus calls for $2.85 EPS on $25.05 billion in revenue. Countervailing risk remains from an Illinois appellate court upholding a $45 million mesothelioma verdict tied to talc claims, while J&J's strategic DePuy Synthes orthopedics divestiture continues to draw investor attention as a portfolio-sharpening move.

0.3074

July 11, 2026Johnson & Johnson shares closed modestly lower, pulling back from recent record highs as investors position cautiously ahead of the company's Q2 2026 earnings release scheduled for July 15. The retreat comes after a strong pre-earnings run fueled by bullish analyst sentiment — Goldman Sachs carries a Buy with a $275 price target, HSBC has a $290 target, and the consensus sits at 'Moderate Buy' — alongside FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF ablation catheter platform, a medtech catalyst that could strengthen J&J's electrophysiology franchise. With analysts projecting Q2 revenue of ~$25 billion (+5.5% YoY) and EPS of $2.86, investor focus is squarely on whether cancer drug momentum — which drove 22% growth in Q1 — can offset ongoing Stelara biosimilar headwinds. Some traders are hedging the run-up, with unusual put option activity noted after the stock's recent surge to near all-time highs.

-0.8182

July 10, 2026Johnson & Johnson closed modestly lower, pulling back from near record-highs as broader market pressure from escalating U.S.-Iran tensions and rising oil prices weighed on sentiment. The decline came despite broadly constructive fundamentals: the company recently received FDA approval for its dual-energy THERMOCOOL SMARTTOUCH SF medtech platform, Goldman Sachs highlighted strong conviction in J&J's pipeline (notably Icotyde), and analysts widely expect a solid Q2 beat when earnings are reported July 15 — with consensus targeting $25B in revenue and $2.86 EPS. Jim Cramer flagged the stock as likely to deliver strong drug news, while the healthcare sector (XLV) also slipped, suggesting the pullback reflects macro-driven rotation rather than any company-specific concern.

-1.6325

July 9, 2026Johnson & Johnson shares declined modestly, pulling back from recent highs as broader market risk-off sentiment — triggered by the breakdown of the U.S.-Iran ceasefire and surging oil prices — weighed on equities. The retreat came despite meaningful company-specific catalysts: J&J received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF cardiac ablation platform, and analysts at Citigroup and Morgan Stanley raised price targets to $298 and $284, respectively. With Q2 earnings scheduled for July 15 and analyst consensus projecting ~$25B in revenue, investors are closely watching for continued momentum from cancer drug sales ahead of a key print. In after-hours trading, shares recovered about half the day's losses.

-1.4369

Barron's · July 16, 2026Johnson & Johnson CFO Says Guidance Hike Is Just the StartInvestor's Business Daily · July 15, 2026J&J Dipped On Its Report, Why Intuitive, Others CelebratedQuartz · July 15, 2026Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strengthCNBC · July 15, 2026J&J quarterly earnings beat Wall Street estimates on strength of medicines unitWSJ · July 15, 2026Johnson & Johnson Bumps Up Guidance as Sales RiseBusiness Wire · July 15, 2026Johnson & Johnson reports Q2 2026 results, raises 2026 outlookInvesting.com · July 15, 2026Earnings call transcript: Johnson & Johnson tops Q2 2026 estimates and lifts outlookThe Globe and Mail · July 14, 2026Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
Benzinga · July 17, 2026Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $270 Price Target
Benzinga · July 16, 2026Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to $265
Benzinga · July 16, 2026Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst
Mt Newswire · July 16, 2026Johnson & Johnson's Innovative Medicine Segment Momentum Continues to Build into 2027, RBC Says
Benzinga · July 16, 2026Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $272
Benzinga · July 16, 2026Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to $294
Benzinga · July 16, 2026Johnson & Johnson Unit DePuy Synthes Acquires Expanding Innovations, A Maker Of Expandable Implant Technology For Spinal Surgery; Financial Terms Not Disclosed
Mt Newswire · July 16, 2026Stifel Adjusts Price Target on Johnson & Johnson to $260 From $250, Maintains Hold Rating

Peers

S&P 500SPX · $7,457.69-1.01%Pfizer Inc.PFE · $25.05-0.36%Merck & Co., Inc.MRK · $127.50-0.10%AbbVie Inc.ABBV · $254.49+0.04%Eli Lilly and CompanyLLY · $1,179.09+0.85%Bristol-Myers Squibb CompanyBMY · $60.74+0.38%Novartis AGNVS · $153.76+0.67%AstraZeneca PLCAZN · $168.90-0.23%Roche Holding AGRO.SW · 339.60+0.83%Abbott LaboratoriesABT · $100.67+1.86%Amgen Inc.AMGN · $366.29-1.42%The Procter & Gamble CompanyPG · $149.96-1.02%